Roche’s Tecentriq Glows In Pivotal Trial For Early Lung Cancer
Immunotherapy Improves DFS In Early NSCLC
Positive pivotal results with Tecentriq in early post-surgery lung cancer should give Roche’s PD-L1 inhibitor pole position within its class for the blockbuster indication. But rivals are hot on its tail.
